Dynavax Technologies Corp
NASDAQ:DVAX

Watchlist Manager
Dynavax Technologies Corp Logo
Dynavax Technologies Corp
NASDAQ:DVAX
Watchlist
Price: 12.42 USD 0.49% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
Dynavax Technologies Corp?
Write Note

Dynavax Technologies Corp
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dynavax Technologies Corp
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Dynavax Technologies Corp
NASDAQ:DVAX
PP&E Net
$59.2m
CAGR 3-Years
-1%
CAGR 5-Years
-1%
CAGR 10-Years
22%
Abbvie Inc
NYSE:ABBV
PP&E Net
$5.1B
CAGR 3-Years
0%
CAGR 5-Years
10%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
PP&E Net
$5.4B
CAGR 3-Years
2%
CAGR 5-Years
1%
CAGR 10-Years
14%
Amgen Inc
NASDAQ:AMGN
PP&E Net
$6.2B
CAGR 3-Years
7%
CAGR 5-Years
3%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
PP&E Net
$2.5B
CAGR 3-Years
23%
CAGR 5-Years
26%
CAGR 10-Years
13%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
PP&E Net
$4.4B
CAGR 3-Years
9%
CAGR 5-Years
10%
CAGR 10-Years
18%
No Stocks Found

Dynavax Technologies Corp
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. The company is headquartered in Emeryville, California and currently employs 311 full-time employees. The company went IPO on 2004-02-19. The firm's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The firm also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The firm is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). The company is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), plague, Tdap, seasonal influenza, universal influenza, and shingles.

DVAX Intrinsic Value
7.57 USD
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Dynavax Technologies Corp's PP&E Net?
PP&E Net
59.2m USD

Based on the financial report for Sep 30, 2024, Dynavax Technologies Corp's PP&E Net amounts to 59.2m USD.

What is Dynavax Technologies Corp's PP&E Net growth rate?
PP&E Net CAGR 10Y
22%

Over the last year, the PP&E Net growth was -3%. The average annual PP&E Net growth rates for Dynavax Technologies Corp have been -1% over the past three years , -1% over the past five years , and 22% over the past ten years .

Back to Top